Earnings, deals and disclosures from Japan's listed pharma & healthcare companies, in English.
Eisai and Biogen launched a self-injectable weekly Leqembi pen in Japan at a listed ¥27,141 per pen, with first doses still given at a medical facility, MRI monitoring unchanged and Eisai's guidance untouched.
Kaken's half-year operating profit rose to ¥10.16bn from ¥180mn, which the company attributes mainly to a $70mn Johnson & Johnson milestone, while Jublia's German launch via Almirall marks its first product rollout in Europe.
Kurabo Industries will buy 21.6mn TAUNS Laboratories shares from Trustar funds and TAUNS's president, taking 20.27% of voting rights with a director nomination right and consent rights, while Trustar keeps 23.85% by TAUNS's estimate.
Shionogi drew an unsecured ¥300bn bridge loan from Sumitomo Mitsui Banking Corporation on 10 November to fund its IntraBio purchase, and plans to refinance it into longer-term funding before the 29 October 2027 repayment date.
Leqembi sales rose 49.7% to ¥61.5bn in Eisai's first half, with the US self-injector IQLIK launched in August and full-year guidance of ¥70bn operating profit left unchanged.
Kyorin Pharmaceutical's operating guide swings from a ¥2bn profit to a ¥4.9bn loss for the year to March 2027, after it counted upfront fees for the Edesa EB05 licence and a second deal not yet signed.
Cancer drugs Enhertu and Datroway drove a 46.9% jump in Daiichi Sankyo's first-half core operating profit to ¥221.3bn, while only 30% of its healthcare unit has passed to Suntory Holdings, with control due to transfer in June 2027.
MSD has begun a Phase 1 trial of a PDPS-derived peptide candidate for inflammatory disease, and PeptiDream expects to book an undisclosed milestone fee as fourth-quarter revenue, already within its full-year forecast.
Nxera Pharma will receive $100mn upfront from AbbVie for a phase 1 bowel-disease drug, and it has fixed 2026 revenue guidance at ¥48.8bn, provided the deal closes by 31 December and its auditor agrees to the accounting.
Kissei's operating profit swung to ¥1.69bn from a ¥6.84bn loss in the half year, but impairment and inventory losses on assets tied to a drug facing approval proceedings cut net profit 33.3% and the full-year net profit guide to ¥10.0bn.
Astellas lifted its full-year core operating profit forecast to ¥700bn from ¥620bn after first-half sales rose 23.4%, though currency added ¥41.2bn to core profit and the new guide assumes a weaker yen than April's.
Kyowa Kirin books its half of the US KOMZIFTI profit-share with Kura Oncology as selling expense because the nine-month net result was negative, while currency and an Amgen contract release helped lift core operating profit 46.8%.
Otsuka Holdings lifted its year-to-December core profit forecast to ¥500bn from ¥470bn, with a newly launched IgA nephropathy drug and its antipsychotic offsetting a 31.1% nine-month sales fall in its kidney-disease drug after US generic entry.
Takeda's half-year net profit rose 171.6% on a 4.1% effective tax rate, yet core operating profit grew just 0.7% at constant currency, even as the drugmaker raised its full-year profit forecasts.
Kissei Pharmaceutical lifted its interim operating profit forecast to ¥1.6bn from ¥500mn, but cut net profit to ¥5.1bn from ¥7.4bn after factoring in special losses on assets for a drug facing approval-revocation proceedings.
Chugai Pharmaceutical's nine-month revenue rose 17.2%, with domestic sales helped by wholesaler shipments brought forward ahead of an ERP launch, yet full-year Core guidance of 6.9% revenue growth stays unchanged.
Tillotts, Zeria's Swiss subsidiary, has signed to buy all of Haupt Pharma Wülfling, the German site that makes most of its Asacol, from Aenova; the price is undisclosed and closing is planned for January 2027 or later, subject to approvals.
Otsuka says its final two-year VISIONARY data show one composite kidney event among 259 VOYXACT patients against 28 among 251 on placebo, and a supplemental FDA filing seeking full approval is complete.
A Japanese drug panel concluded Steboronine can be approved for recurrent meningioma, but formal approval is pending, and Stella Pharma expects only a slight effect on earnings in the year to March 2027.
Japan's health ministry has asked doctors to withhold Kissei's avacopan from new patients and, as a rule, to consider stopping or switching those already taking it, after a panel found the approval data may be unreliable.
Nxera Pharma has withdrawn its 10% cap on share-based pay and will grant three executive officers options over up to 6.65mn shares, about 7.2% of shares outstanding, which vest only if price hurdles from ¥2,200 to ¥10,000 are met.
Kringle Pharma said the FDA review of its IND for oremepermin alfa has ended and the application is in effect; the company is preparing a US Phase III trial in acute spinal cord injury, with no partner or start date named.
Santen Pharmaceutical's Chongqing joint venture, in liquidation since 2024, will apply for bankruptcy with about ¥3.3bn of liabilities, but the company says a fully provisioned ¥2bn loan means no new loss.
Daito, Meiji Seika Pharma and the Development Bank of Japan plan a joint company to take over Kyorin Pharmaceutical's generic business, with the absorption split set for March 31, 2027 and closing on April 1.